2023
A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response-Dependent Survival of Quiescent Cancer Cells.
Calvo V, Zheng W, Adam-Artigues A, Staschke K, Huang X, Cheung J, Nobre A, Fujisawa S, Liu D, Fumagalli M, Surguladze D, Stokes M, Nowacek A, Mulvihill M, Farias E, Aguirre-Ghiso J. A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response-Dependent Survival of Quiescent Cancer Cells. Clinical Cancer Research 2023, 29: 5155-5172. PMID: 37982738, PMCID: PMC10842363, DOI: 10.1158/1078-0432.ccr-23-1427.Peer-Reviewed Original ResearchCancer cellsIntegrated stress responsePERK inhibitionRounds of therapyPERK inhibitorDormant cancer cellsQuiescent cancer cellsMicro-metastatic lesionsAnti-proliferative therapiesMetastasis biopsiesMetastatic burdenCDK4/6 inhibitorsPDX modelsSingle-cell gene expression profilingHER2 activityMetastatic progressionGene expression profilingSurvival factorUnresolved ER stressHigh expressionMouse syngeneicER stressMetastasisHER2Therapy
2021
Temporal and spatial topography of cell proliferation in cancer.
Kabraji S, Gaglia G, Argyropoulou D, Dai Y, Wang S, Bergholz J, Coy S, Lin J, Jeselsohn R, Metzger O, Winer E, Dillon D, Zhao J, Sorger P, Santagata S. Temporal and spatial topography of cell proliferation in cancer. Journal Of Clinical Oncology 2021, 39: 3122-3122. DOI: 10.1200/jco.2021.39.15_suppl.3122.Peer-Reviewed Original ResearchCell cycle stateCancer cellsBreast cancerTumor-infiltrating immune cellsDisease-free survivalCell cycle protein expressionCell proliferationDormant cancer cellsCancer cell proliferationQuiescent cancer cellsCycle stateCancer stem cellsSame primary tumorNeoadjuvant therapyProliferative cancer cellsAdjuvant therapyClinical outcomesColorectal cancerPrimary tumorImmune cellsUntreated tumorsDiverse tumor typesUnique tumorProliferation indexProliferative index
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply